Clinical Trials for Prinicipal Investigator: Krishnansu Tewari

12 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
GOG-0237 Comparative Analysis Of CA-IX, p16, Proliferative Markers And Human Papilloma Virus (HPV) In The Diagnosis Of Significant Cervical Lesions In Patients With A Cytologic Diagnosis Of Atypical Glandular Cells (AGC) Open
GOG-0263 (CIRB) Randomized Phase III Clinical Trial Of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy And Pelvic Lymphadenectomy Open
GOG-0278 Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer Open
GOG-0279 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Open
GOG-0286B (CIRB) A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Open
GOG-0724 (CIRB) Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Open
GOG-3009 Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV Open
UCI-13-09 Molecular Analysis of Alterations of the PI3K/AKT/mTOR Pathway in Lynch Syndrome-Associated Endometrial Cancer with Clinicopathologic Correlation Open
UCI-15-31 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Open
UCI-16-52 A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation Open
UCI-16-69 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
UCI-16-71 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open